MCID: CRC006
MIFTS: 55

Carcinoid Syndrome malady

Rare diseases, Endocrine diseases, Neuronal diseases, Cancer diseases categories

Aliases & Classifications for Carcinoid Syndrome

About this section

Aliases & Descriptions for Carcinoid Syndrome:

Name: Carcinoid Syndrome 42
Carcinoid Tumor 42 61
Apudoma 42 61
Carcinoid Tumor No Icd-O Subtype 61
Malignant Carcinoid Syndrome 61
Endocrine Gland Neoplasms 61
 
Carcinoid Tumor Syndrome 42
Neuroendocrine Tumors 61
Neuroendocrine Tumor 42
Carcinoid Tumors 32
Endocrine Tumor 42
Carcinoid 44


Classifications:



External Ids:

ICD1025 E34.0

Summaries for Carcinoid Syndrome

About this section
NIH Rare Diseases:42 A carcinoid tumor is a rare, slow-growing cancer that usually starts in the lining of the digestive tract (appendix, stomach, small intestine, colon, rectum) or in the lungs but may occur elsewhere. because carcinoid tumors grow slowly and don't produce symptoms in the early stages, affected individuals may have the tumor for years before being diagnosed. in later stages the tumor sometimes produces hormones that can cause carcinoid syndrome. the syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. surgery is the main treatment for a carcinoid tumor. if it does not spread to other parts of the body, surgery can typically cure the cancer. last updated: 4/9/2012

MalaCards based summary: Carcinoid Syndrome, also known as carcinoid tumor, is related to apudoma and pernicious anemia. An important gene associated with Carcinoid Syndrome is SST (somatostatin), and among its related pathways are Sympathetic Nerve Pathway (Neuroeffector Junction) and SIDS Susceptibility Pathways. The drug interferon alfa-2b and the compounds 111in-pentetreotide and streptozotocin have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and colon, and related mouse phenotypes are adipose tissue and tumorigenesis.

MedlinePlus:32 Carcinoid tumors are rare, slow-growing cancers. they usually start in the lining of the digestive tract or in the lungs. they grow slowly and don't produce symptoms in the early stages. as a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. in later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. the syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. surgery is the main treatment for carcinoid tumors. if they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia:64 Carcinoid syndrome refers to the array of symptoms that occur secondary to carcinoid tumors. The... more...

Related Diseases for Carcinoid Syndrome

About this section

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 441)
idRelated DiseaseScoreTop Affiliating Genes
1apudoma31.9CALCA, SST
2pernicious anemia31.4GAST
3atrophic gastritis31.0CHGA, SST, MEN1, GAST
4acinar cell carcinoma30.8CHGA, GAST
5granular cell tumor30.8ENO2, SYP
6constipation30.7PYY, HTR3A
7cushing's syndrome30.7SST, GHRH
8neuroendocrine tumor30.7CALCA, GHRH, CHGA, SST
9islet cell tumor30.6GAST, SST
10angiodysplasia30.6SST
11cholelithiasis30.6UGT1A1, SST
12sertoli cell tumor30.6SYP, ENO2
13vipoma30.5CALCA, SST
14zollinger-ellison syndrome30.5GAST, GHRH, MEN1, SST, CHGA
15neurofibromatosis30.5MEN1, ENO2, SST
16pancreatic cancer30.5PYY, GAST, SST, NTS
17merkel cell carcinoma30.5SYP, ENO2, CHGA
18tubular adenocarcinoma30.5SYP, CHGA, ENO2
19hypercalcemia30.5MEN1, CALCA, GAST, CHGA
20ependymoma30.5SYP, MEN1, ENO2
21hyperinsulinemic hypoglycemia30.4GAST, SST
22endocrine gland cancer30.4SST, SYP, GAST, CHGA
23multiple endocrine neoplasia30.4MEN1, CHGA, CALCA, GAST
24lung cancer30.4SYP, ENO2, CHGA, VEGFA
25ganglioneuroblastoma30.3ENO2, NPY, SYP
26hemangioma30.3MEN1, IFNA2, VEGFA
27parathyroid adenoma30.3CALCA, MEN1, CHGA
28duodenal ulcer30.3GAST, SST
29phaeochromocytoma30.3CHGA, NPY, CALCA
30diarrhea30.3UGT1A1, CHGA, HTR3A, PYY, CALCA, SST
31gastritis30.3CHGA, SST, GAST, NTS
32neuroblastoma30.3KNG1, ENO2, SYP, NTS
33esophagitis30.3NTS, GAST
34primary hyperparathyroidism30.2GAST, CALCA, MEN1, CHGA
35hyperparathyroidism30.2CALCA, CHGA, GAST, MEN1
36prostate cancer30.2CHGA, NTS, ENO2, GHRH, IGF1
37von hippel-lindau syndrome30.2NPY, VEGFA, MEN1
38acromegaly30.2IGF1, SST, MEN1, GHRH
39hypopituitarism30.2SST, IGF1, GHRH
40multiple endocrine neoplasia 130.2SST, MEN1, GAST, CHGA
41thyroid cancer30.2TKT, SST, CHGA, CALCA
42prolactinoma30.1SST, IGF1, CHGA, MEN1
43somatostatinoma30.1GAST, CALCA, GHRH, SST, CHGA
44glucagonoma30.0CHGA, ENO2, GAST, GHRH, MEN1, SST
45gastrinoma30.0GAST, SYP, MEN1, SST, CHGA, ENO2
46hyperinsulinism30.0SST, IGF1, NPY
47paraganglioma29.9ENO2, GAST, CALCA, SYP, MEN1, SST
48dementia29.9SYP, KNG1, HTR3A
49pituitary adenoma29.9SYP, NTS, SST, CHGA, IGF1, MEN1
50glioblastoma29.9TKT, GHRH, KNG1, VEGFA

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to carcinoid syndrome

Symptoms for Carcinoid Syndrome

About this section

Drugs & Therapeutics for Carcinoid Syndrome

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.

Drug clinical trials:

Search ClinicalTrials for Carcinoid Syndrome

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Carcinoid Syndrome

About this section

Anatomical Context for Carcinoid Syndrome

About this section

MalaCards organs/tissues related to Carcinoid Syndrome:

31
Lung, Heart, Colon, Small intestine, Appendix, Liver, Skin, Testes, Pituitary, Bone, Ovary, Testis, Cervix, Thymus, Pancreas, Prostate

Animal Models for Carcinoid Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Carcinoid Syndrome:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.3PYY, NTS, TKT, NPY, IGF1
2MP:00020068.2GAST, CALCA, MEN1, VEGFA, IGF1
3MP:00028737.9SYP, CALCA, NPY, SST, VEGFA, IGF1
4MP:00053897.8VEGFA, GHRH, HTR3A, MEN1, TKT, IGF1
5MP:00053677.8TKT, NPY, CALCA, HTR3A, CHGA, VEGFA
6MP:00053797.6TKT, GAST, GHRH, HTR3A, MEN1, CHGA
7MP:00053787.0MEN1, PYY, TKT, NPY, GHRH, NTS
8MP:00053866.9PYY, VEGFA, TKT, HTR3A, NTS, CALCA
9MP:00053766.1KNG1, NTS, GHRH, CALCA, HTR3A, MEN1
10MP:00036315.8NTS, GHRH, SYP, CALCA, ENO2, NPY

Publications for Carcinoid Syndrome

About this section

Articles related to Carcinoid Syndrome:

(show top 50)    (show all 498)
idTitleAuthorsYear
1
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. (25012985)
2014
2
Cutaneous scleroderma and malignant carcinoid syndrome. (23517363)
2013
3
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy: clinico-radiological and pathological features. (23771374)
2013
4
Carcinoid syndrome diagnosed by echocardiography. (19217173)
2011
5
Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. (17011239)
2007
6
Carcinoid tumor and carcinoid syndrome. (17021482)
2003
7
(131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. (11417988)
2001
8
Prognostic value of heart rate variability analysis in patients with carcinoid syndrome. (11173898)
2001
9
The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. (9780538)
1998
10
Anesthesia for patients with carcinoid syndrome. (9444534)
1997
11
Obstructive sleep apnoea syndrome (OSAS) as a complication of carcinoid syndrome treated successfully by hepatic artery embolization. (9058639)
1997
12
Update on carcinoid syndrome. (9233098)
1997
13
Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. (8527614)
1995
14
Response to increasing doses of octreotide in a patient with carcinoid syndrome. (7509166)
1993
15
Carcinoid syndrome due to a primary ovarian carcinoid tumour. (8258808)
1993
16
Treatment of carcinoid syndrome with a somatostatin analogue]. (1372969)
1992
17
Chemotherapy responses in carcinoid syndrome. (1827797)
1991
18
Management of carcinoid syndrome. (1924020)
1991
19
POEMS syndrome with idiopathic flushing mimicking carcinoid syndrome. (2029023)
1991
20
Epidural anaesthesia for transurethral resection of the prostate in a patient with carcinoid syndrome. (2322971)
1990
21
Carcinoid syndrome without liver metastasis. (2602263)
1989
22
The carcinoid syndrome. (2457717)
1988
23
Carcinoids and carcinoid syndrome. (2884878)
1987
24
Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. (2893640)
1987
25
Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity. (2887127)
1987
26
The carcinoid syndrome. (2875390)
1986
27
The carcinoid syndrome: palliation by hepatic artery embolization. (2424291)
1986
28
Carcinoid syndrome. Radiology. (3527315)
1986
29
The pentagastrin test in the diagnosis of the carcinoid syndrome. (2412067)
1985
30
On the mode of action of the pentagastrin test in the carcinoid syndrome. (4023617)
1985
31
Carcinoid tumors and carcinoid syndrome. (6592877)
1984
32
Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis. (7092350)
1982
33
Anaesthesia and the carcinoid syndrome. (517724)
1979
34
Carcinoid syndrome and anaesthetic management. (509352)
1979
35
Carcinoid syndrome treated by hepatic embolization. (99001)
1978
36
Use of novel pharmacological agents in carcinoid syndrome: case report. (414163)
1977
37
Unilateral hypoperfusion of the lung and carcinoid syndrome due to bronchial carcinoid tumor. (842945)
1977
38
Blood prostaglandin activity associated with noradrenaline-provoked flush in the carcinoid syndrome. (4833791)
1974
39
Airways obstruction in the carcinoid syndrome. A study of the effect of drugs and other factors. I. Clinical and laboratory findings. (5041785)
1972
40
Cause of flushing in carcinoid syndrome. (4106630)
1971
41
Chest pain in the carcinoid syndrome. (4193351)
1970
42
Alterations of platelet ultrastructure in patients with carcinoid syndrome. (5822315)
1969
43
Gangrene of the small intestine in carcinoid syndrome. (5233491)
1967
44
Carcinoid syndrome associated with psychosis. (5827675)
1965
45
THE MALIGNANT CARCINOID SYNDROME. SYMPTOMS DUE TO HYPERSECRETION OF SEROTONIN. REPORT OF TWO CASES, ONE TREATED BY HEPATIC ARTERY PERFUSION. (14254630)
1965
46
APPENDICEAL CARCINOID WITH CARCINOID SYNDROME. (14166209)
1964
47
THE CARCINOID SYNDROME. (14267547)
1964
48
A malignant bronchial adenoma presenting as a carcinoid syndrome. (13994698)
1963
49
Carcinoid syndrome and hypertension. A case report. (13913540)
1962
50
Serotonin production by bronchial adenomas without the carcinoid syndrome. (14005020)
1961

Variations for Carcinoid Syndrome

About this section

Expression for genes affiliated with Carcinoid Syndrome

About this section
Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for genes affiliated with Carcinoid Syndrome

About this section

Compounds for genes affiliated with Carcinoid Syndrome

About this section

Compounds related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 230)
idCompoundScoreTop Affiliating Genes
1111in-pentetreotide449.7CALCA, SYP, SST, CHGA
2streptozotocin449.3SST, NPY, SYP, IFNA2, CHGA
3lanreotide44 2810.2GHRH, IGF1, CHGA, SST
4haloperidol44 50 28 1 1113.1NPY, SYP, CHGA, NTS, HTR3A, PYY
5yohimbine44 1 28 1112.0PYY, HTR3A, NTS, GAST, NPY
6oxyntomodulin44 6010.0NPY, GAST, NTS, SST, CHGA, PYY
7c-peptide448.8NTS, IGF1, PYY, SST, CHGA, GAST
8propranolol44 28 50 24 1112.8SST, HTR3A, GHRH, CALCA, GAST, CHGA
95-hydroxyindoleacetic acid44 249.7GAST, ENO2, HTR3A, SST, CHGA
10epinephrine44 24 1110.6CHGA, IFNA2, NPY, CALCA, NTS, SST
11mibg448.6CHGA, SST, CALCA, ENO2
12prostaglandin f2alpha448.6IGF1, NPY, CALCA, KNG1, SST
13carbachol44 28 1110.5SST, NTS, NPY, KNG1, GAST, CHGA
14clonidine44 50 28 1111.5NPY, CALCA, GHRH, PYY, IGF1, CHGA
15tetrodotoxin44 60 2810.4NTS, ENO2, NPY, CALCA, HTR3A, PYY
16gnrh448.3PYY, GAST, CHGA, SST, NTS, GHRH
17atropine44 28 1110.3NPY, GAST, CALCA, GHRH, NTS, SST
18nifedipine44 28 50 1111.2NPY, KNG1, NTS, GAST, TKT, GHRH
19isoproterenol44 119.2SST, NPY, GAST, KNG1, CHGA, NTS
20cyclic amp44 249.2CHGA, NTS, GHRH, SYP, CALCA, KNG1
21guanine44 24 1110.2SYP, UGT1A1, CALCA, NTS, CHGA, ENO2
22tamoxifen44 50 28 1111.1CHGA, IGF1, UGT1A1, VEGFA, IFNA2, GHRH
23thyroxine44 249.0UGT1A1, IGF1, SST, IFNA2, NTS, GHRH
24etoposide44 50 60 1111.0IFNA2, CHGA, ENO2, TKT, SYP, UGT1A1
25arginine447.9NPY, SST, CHGA, IGF1, UGT1A1, PYY
26indomethacin44 28 60 1110.9ENO2, NPY, KNG1, UGT1A1, IFNA2, NTS
27amine447.9UGT1A1, PYY, CHGA, HTR3A, NTS, ENO2
28forskolin44 50 119.8GHRH, NTS, CHGA, ENO2, SYP, CALCA
29paraffin447.5NPY, VEGFA, CHGA, NTS, SYP, ENO2
30histamine44 28 249.4CALCA, PYY, KNG1, GAST, NPY, SYP
31thymidine44 248.3GAST, ENO2, TKT, NTS, PYY, UGT1A1
32creatinine447.2IGF1, CHGA, SYP, CALCA, GAST, TKT
33gaba447.2TKT, PYY, CHGA, SST, HTR3A, NTS
34glutamate447.2GHRH, TKT, CHGA, NTS, SYP, GAST
35retinoic acid44 248.2CHGA, IGF1, UGT1A1, SST, IFNA2, SYP
36glucose447.2SST, GAST, NTS, NPY, PYY, ENO2
37cisplatin44 50 60 1110.1IFNA2, TKT, CHGA, HTR3A, VEGFA, UGT1A1
38acth447.0PYY, IGF1, SYP, GHRH, NTS, IFNA2
395-hydroxytryptamine446.9NPY, PYY, CHGA, SST, HTR3A, NTS
40acetylcholine44 50 28 24 1110.8SST, HTR3A, NTS, SYP, CALCA, KNG1
41adenylate446.8TKT, NPY, ENO2, GAST, KNG1, CALCA
42dexamethasone44 50 28 119.6SST, GAST, GHRH, HTR3A, CHGA, VEGFA
43vegf446.4TKT, CHGA, SYP, SST, IFNA2, MEN1
44testosterone44 60 24 119.4ENO2, NPY, TKT, GAST, UGT1A1, IGF1
45dopamine44 28 24 119.3PYY, IGF1, SST, ENO2, GAST, CALCA
46octreotide44 60 28 119.3NPY, ENO2, GAST, CALCA, GHRH, NTS
47calcium44 50 24 119.3GAST, ENO2, NPY, TKT, SYP, PYY
48norepinephrine44 24 118.2CHGA, PYY, SST, HTR3A, NTS, TKT
49estrogen445.5UGT1A1, IGF1, VEGFA, CHGA, MEN1, IFNA2
50tyrosine445.4IFNA2, GAST, KNG1, SYP, NTS, ENO2

GO Terms for genes affiliated with Carcinoid Syndrome

About this section

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet alpha granule lumenGO:00310938.9KNG1, VEGFA, IGF1
2extracellular spaceGO:00056156.6PYY, IGF1, VEGFA, SST, IFNA2, GHRH
3extracellular regionGO:00055766.1NPY, PYY, IGF1, VEGFA, CHGA, SST

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1regulation of blood pressureGO:00082179.7CHGA, CALCA, NPY
2positive regulation of insulin-like growth factor receptor signaling pathwayGO:00435689.6IGF1, GHRH
3feeding behaviorGO:00076319.6NPY, CALCA, PYY
4activation of protein kinase activityGO:00321479.5CALCA, VEGFA
5cell-cell signalingGO:00072679.4PYY, SST, IFNA2, GHRH, CALCA
6cellular component movementGO:00069289.3NPY, IGF1, PYY
7digestionGO:00075869.2NPY, HTR3A, SST, UGT1A1, PYY
8platelet degranulationGO:00025768.9KNG1, VEGFA, IGF1
9blood coagulationGO:00075968.3KNG1, IFNA2, VEGFA, IGF1

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuropeptide hormone activityGO:00051849.6NPY, NTS, PYY
2hormone activityGO:00051798.3GAST, CALCA, SST, IGF1, PYY

Sources for Carcinoid Syndrome

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet